Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells

Cell Death Dis. 2010 Dec 9;1(12):e105. doi: 10.1038/cddis.2010.85.

Abstract

Advanced prostate cancers are known to acquire not only invasive capabilities but also significant resistance to chemotherapy-induced apoptosis. To understand how microRNAs (miRNAs) may contribute to prostate cancer resistance to apoptosis, we compared microRNA expression profiles of a benign prostate cancer cell line WPE1-NA22 and a highly malignant WPE1-NB26 cell line (derived from a common lineage). We found that miR-205 and miR-31 are significantly downregulated in WPE1-NB26 cells, as well as in other cell lines representing advanced-stage prostate cancers. Antiapoptotic genes BCL2L2 (encoding Bcl-w) and E2F6 are identified as the targets of miR-205 and miR-31, respectively. By downregulating Bcl-w and E2F6, miR-205 and miR-31 promote chemotherapeutic agents-induced apoptosis in prostate cancer cells. The promoter region of the miR-205 gene was cloned and was found to be hypermethylated in cell lines derived from advanced prostate cancers, contributing to the downregulation of the gene. Treatment with DNA methylation inhibitor 5-aza-2'-deoxycytidine induced miR-205 expression, downregulated Bcl-w, and sensitized prostate cancer cells to chemotherapy-induced apoptosis. Thus, downregulation of miR-205 and miR-31 has an important role in apoptosis resistance in advanced prostate cancer.

Keywords: Bcl-w; E2F6; apoptosis; miR-205; miR-31; prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / therapeutic use
  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Apoptosis Regulatory Proteins / genetics
  • Apoptosis Regulatory Proteins / metabolism
  • Apoptosis Regulatory Proteins / physiology
  • Azacitidine / analogs & derivatives
  • Azacitidine / therapeutic use
  • Cell Line, Tumor
  • DNA Methylation
  • DNA Modification Methylases / antagonists & inhibitors
  • Decitabine
  • Down-Regulation
  • Drug Resistance, Neoplasm / genetics*
  • E2F6 Transcription Factor / genetics
  • E2F6 Transcription Factor / metabolism
  • E2F6 Transcription Factor / physiology
  • Humans
  • Male
  • Mice
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Promoter Regions, Genetic
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism

Substances

  • Antimetabolites, Antineoplastic
  • Apoptosis Regulatory Proteins
  • BCL2L2 protein, human
  • E2F6 Transcription Factor
  • E2F6 protein, human
  • MIRN205 microRNA, human
  • MIRN31 microRNA, human
  • MicroRNAs
  • Decitabine
  • DNA Modification Methylases
  • Azacitidine